ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement This License allows abm to develop and commercialize products using CRISPR/Cas9 technology. Dublin, Ireland and Vancouver,…
“Although CVC and Broad’s CRISPR/Cas9 gene editing patents currently coexist in the US, pending federal circuit appeal, the picture is clearer in the EPO opposition…
Find out what role #CRISPR has to play in the new bio-industrial revolution in our latest article on #synbio and CRISPR’d #chemicals @GENbio https://www.genengnews.com/topics/bioprocessing/crispr-made-greener-products-and-processes-in-industrial-biotechnology/
In The Medicine Maker, ERS Genomics CEO, Eric Rhodes explores the power and flexibility of CRISPR/Cas9 for the antibody manufacturing pipeline, including for next-generation antibody-drug…
Dublin, Ireland, January 5, 2023: ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions and methods of using CRISPR/Cas9…
Dublin, Ireland, December 1, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license…